Published in J Clin Pharmacol on October 01, 2004
Safety and efficacy of statins in Asians. Am J Cardiol (2006) 1.65
Consensus statement on management of dyslipidemia in Indian subjects. Indian Heart J (2014) 1.57
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol (2007) 1.14
A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer. Invest New Drugs (2013) 1.01
Addressing phenoconversion: the Achilles' heel of personalized medicine. Br J Clin Pharmacol (2015) 0.90
The role of soy in vegetarian diets. Nutrients (2010) 0.86
Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review. Genet Med (2014) 0.86
Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects. Eur J Clin Pharmacol (2012) 0.82
A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. Br J Clin Pharmacol (2011) 0.82
Metabolic capabilities of cytochrome P450 enzymes in Chinese liver microsomes compared with those in Caucasian liver microsomes. Br J Clin Pharmacol (2012) 0.80
Pharmacogenetics aspects of oral anticoagulants therapy. J Med Life (2015) 0.79
Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer. Sci Rep (2015) 0.78
A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab (2014) 0.78
Analysis of CYP2C9*2, CYP2C9*3 and VKORC1 -1639 G>A polymorphisms in a population from South-Eastern Europe. J Cell Mol Med (2012) 0.77
Comparison of the pharmacokinetics, pharmacodynamics and tolerability of tezosentan between caucasian and Japanese subjects. Br J Clin Pharmacol (2006) 0.77
Inhibition of Human Cytochrome P450 Enzymes by Allergen Removed Rhus verniciflua Stoke Standardized Extract and Constituents. Evid Based Complement Alternat Med (2014) 0.77
Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects. AAPS J (2013) 0.75
Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration. Acta Pharmacol Sin (2015) 0.75
The need for multicentre cardiovascular clinical trials in Asia. Nat Rev Cardiol (2013) 0.75
Re-Evaluation of Efficacy of Moderate-Intensity Statins in Korean Patients with Type 2 Diabetes Mellitus. Diabetes Metab J (2017) 0.75
The role of CYP3A5 polymorphism and dose adjustments following conversion of twice-daily to once-daily tacrolimus in renal transplant recipients. Transplant Res (2016) 0.75
Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections. Antimicrob Agents Chemother (2017) 0.75
Paroxetine versus Venlafaxine and Escitalopram in Korean Patients with Major Depressive Disorder: A Randomized, Rater-blinded, Six-week Study. Clin Psychopharmacol Neurosci (2017) 0.75
A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med (2013) 7.09
CYP4F2 genetic variant alters required warfarin dose. Blood (2008) 4.23
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet (2013) 3.21
Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. Clin Pharmacol Ther (2006) 3.06
Preserving the genetic integrity of human embryonic stem cells. Nat Biotechnol (2005) 3.03
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood (2010) 2.93
Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci. Am J Hum Genet (2012) 2.53
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J Antimicrob Chemother (2005) 2.50
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: overcoming challenges of real-world implementation. Clin Pharmacol Ther (2013) 2.39
Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet (2006) 2.32
beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure. Clin Pharmacol Ther (2005) 2.20
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood (2008) 2.18
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother (2004) 2.10
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Tissue concentrations: do we ever learn? J Antimicrob Chemother (2007) 1.92
Plasma renin activity predicts blood pressure responses to beta-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertens (2010) 1.90
Stroke Genetics Network (SiGN) study: design and rationale for a genome-wide association study of ischemic stroke subtypes. Stroke (2013) 1.80
Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials (2010) 1.72
Chromosome 9p21 haplotypes and prognosis in white and black patients with coronary artery disease. Circ Cardiovasc Genet (2011) 1.69
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue. Antimicrob Agents Chemother (2004) 1.64
G protein receptor kinase 4 polymorphisms: β-blocker pharmacogenetics and treatment-related outcomes in hypertension. Hypertension (2012) 1.59
Clinical pharmacogenetics implementation: approaches, successes, and challenges. Am J Med Genet C Semin Med Genet (2014) 1.57
Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenet Genomics (2005) 1.53
Hypertension susceptibility loci and blood pressure response to antihypertensives: results from the pharmacogenomic evaluation of antihypertensive responses study. Circ Cardiovasc Genet (2012) 1.52
Pharmacogenomic association of nonsynonymous SNPs in SIGLEC12, A1BG, and the selectin region and cardiovascular outcomes. Hypertension (2013) 1.52
Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am J Hum Genet (2008) 1.50
Protein binding: do we ever learn? Antimicrob Agents Chemother (2011) 1.46
TET2 and CSMD1 genes affect SBP response to hydrochlorothiazide in never-treated essential hypertensives. J Hypertens (2015) 1.43
Genetic warfarin dosing: tables versus algorithms. J Am Coll Cardiol (2011) 1.43
Sustained restoration of autonomic balance with long- but not short-acting metoprolol in patients with heart failure. J Card Fail (2006) 1.41
Genetic and pharmacogenetic associations between NOS3 polymorphisms, blood pressure, and cardiovascular events in hypertension. Am J Hypertens (2009) 1.40
KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics (2007) 1.40
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci (2010) 1.37
How important are gender differences in pharmacokinetics? Clin Pharmacokinet (2002) 1.37
AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives. Pharm Res (2007) 1.35
Characterizing the effects of caspofungin on Candida albicans, Candida parapsilosis, and Candida glabrata isolates by simultaneous time-kill and postantifungal-effect experiments. Antimicrob Agents Chemother (2006) 1.34
A haplotype-based algorithm for multilocus linkage disequilibrium mapping of quantitative trait loci with epistasis. Genetics (2003) 1.31
Protocols for cytogenetic studies of human embryonic stem cells. Methods (2008) 1.30
Collection of genomic DNA by the noninvasive mouthwash method for use in pharmacogenetic studies. Pharmacotherapy (2002) 1.28
Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet (2013) 1.27
Highly variable mRNA expression and splicing of L-type voltage-dependent calcium channel alpha subunit 1C in human heart tissues. Pharmacogenet Genomics (2006) 1.27
Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers. J Agric Food Chem (2006) 1.26
Genetics and cardiovascular disease: a policy statement from the American Heart Association. Circulation (2012) 1.26
Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet (2010) 1.25
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs. Int J Antimicrob Agents (2002) 1.24
Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents (2002) 1.23
Sequencing complex diseases With HapMap. Genetics (2004) 1.22
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PLoS One (2012) 1.21
Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. Pharmacogenet Genomics (2011) 1.20
Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension. Clin Pharmacol Ther (2004) 1.20
Duffy antigen modifies the chemokine response in human endotoxemia. Crit Care Med (2008) 1.20
Relation of beta(2)-adrenoceptor haplotype to risk of death and heart transplantation in patients with heart failure. Am J Cardiol (2006) 1.19
Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother (2008) 1.16
Effects of high-fructose corn syrup and sucrose on the pharmacokinetics of fructose and acute metabolic and hemodynamic responses in healthy subjects. Metabolism (2011) 1.15
Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension (2009) 1.15
Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure. Pharmacogenet Genomics (2007) 1.15
Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther (2005) 1.14
Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension (2013) 1.14
Pharmacogenetics of beta-blockers. Pharmacotherapy (2007) 1.13
Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains. Int J Antimicrob Agents (2006) 1.13
Chromosome 7 and 19 trisomy in cultured human neural progenitor cells. PLoS One (2009) 1.13
Rationale and design of the Clarification of Optimal Anticoagulation through Genetics trial. Am Heart J (2013) 1.12
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenet Genomics (2011) 1.12
Once-daily tobramycin in cystic fibrosis: better for clinical outcome than thrice-daily tobramycin but more resistance development? J Antimicrob Chemother (2006) 1.12
Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents (2005) 1.11
Tobacco smoke exposure induces nicotine dependence in rats. Psychopharmacology (Berl) (2009) 1.11
Hyperforin in St. John's wort drug interactions. Eur J Clin Pharmacol (2006) 1.10
Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One (2013) 1.10
Ertapenem in critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother (2006) 1.09
Modeling sequence-sequence interactions for drug response. Bioinformatics (2007) 1.08
Warfarin: an old drug but still interesting. Pharmacotherapy (2008) 1.08
Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem Pharmacol (2009) 1.08
Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am (2005) 1.07
Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci (2002) 1.06
Population kinetics, efficacy, and safety of dichloroacetate for lactic acidosis due to severe malaria in children. J Clin Pharmacol (2003) 1.05
Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: results from GENEtic Substudy of the INternational VErapamil SR-trandolapril STudy (INVEST-GENES). Am Heart J (2008) 1.05
Pharmacokinetics and bioavailability of herbal medicinal products. Phytomedicine (2002) 1.04
Comparison of cytochrome P450 2C9 genotyping methods and implications for the clinical laboratory. Pharmacotherapy (2004) 1.04
Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers. Int J Antimicrob Agents (2012) 1.03
Human polymorphisms in the glutathione transferase zeta 1/maleylacetoacetate isomerase gene influence the toxicokinetics of dichloroacetate. J Clin Pharmacol (2011) 1.03
Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents (2010) 1.03
Cardiovascular pharmacogenomics. Circ Res (2011) 1.03
Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol (2003) 1.02
Association between the chromosome 9p21 locus and angiographic coronary artery disease burden: a collaborative meta-analysis. J Am Coll Cardiol (2013) 1.02
Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents (2005) 1.02
Genetics and genomics for the prevention and treatment of cardiovascular disease: update: a scientific statement from the American Heart Association. Circulation (2013) 1.01
Pharmacokinetics of anthocyanins and antioxidant effects after the consumption of anthocyanin-rich acai juice and pulp (Euterpe oleracea Mart.) in human healthy volunteers. J Agric Food Chem (2008) 1.01
AAPS-FDA Workshop White Paper: microdialysis principles, application, and regulatory perspectives. J Clin Pharmacol (2007) 1.01
Soft tissue penetration of cefuroxime determined by clinical microdialysis in morbidly obese patients undergoing abdominal surgery. Int J Antimicrob Agents (2009) 1.01
Genetic variation in PEAR1 is associated with platelet aggregation and cardiovascular outcomes. Circ Cardiovasc Genet (2013) 0.99
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev (2013) 0.99
Ertapenem: the new carbapenem 5 years after first FDA licensing for clinical practice. Expert Opin Pharmacother (2007) 0.98
Population pharmacokinetic model of human insulin following different routes of administration. J Clin Pharmacol (2010) 0.98
PK/PD: new insights for antibacterial and antiviral applications. Curr Opin Pharmacol (2008) 0.98
In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother (2009) 0.98